Dean Spurden

Predictors of real-world response in adults treated with botulinumtoxin-A for upper limb spasticity

Klemens Fheodoroff, Jorge Jacinto, Stephen Ashford, Natalya Danchenko et autres

Background: To explore predictors of treatment response in adults receiving botulinumtoxin-A (BoNT-A) for upper limb spasticity (ULS) and to describe the association between response and concomitant medication, professional physical therapy, and quality of life (QoL). Methods: This was a secondary analysis of …

us, pt, gb, fr (code pays fourni par la source)

Botulinum Neurotoxin Treatment Dynamics and Persistence Over 2 Years in Patients With Cervical Dystonia or Spasticity: A Retrospective Claims Database Analysis

David M. Simpson, Jonathan Bouchard, Simon Page, Dean Spurden et autres

us, gb (code pays fourni par la source)

PCR164 Adherence to Botulinumtoxin Treatment: A 2-Year Retrospective Claims Database Analysis

David M. Simpson, Jonathan Bouchard, Sean Page, Dean Spurden et autres

us, gb (code pays fourni par la source)

Adherence to Botulinumtoxin Treatment: A 2-year Retrospective Claims Database Analysis (P12-11.008)

David Simpson, Jonathan Bouchard, Simon Page, Dean Spurden et autres

Objective: To describe treatment dynamics and persistence with botulinumtoxin (BoNT) over 2 years in a retrospective longitudinal study. Background: Understanding the use of BoNT in clinical practice is essential for improving clinical care. Real-world evidence on long-term persistence with BoNT therapy is …

us, fr (code pays fourni par la source)

Health-Related Quality of Life Among Patients With HR+/HER2– Early Breast Cancer

Carmen Criscitiello, Dean Spurden, James Piercy, A. Rider et autres

it, gb, us (code pays fourni par la source)

CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies

Nadia Harbeck, Meaghan Bartlett, Dean Spurden, Becky Hooper et autres

Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in …

de, ca, us (code pays fourni par la source)

CN1 HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH EARLY BREAST CANCER: A MULTINATIONAL STUDY

Ernest H. Law, Dean Spurden, James Piercy, Roma D. Williams et autres

us, gb, it (code pays fourni par la source)

87P Patient-reported and cancer-specific health-related quality of life among patients with early stage HR+/HER2- breast cancer (BC)

Carmen Criscitiello, Dean Spurden, A. Rider, Rhys Williams et autres

it, gb, us (code pays fourni par la source)

88P Latent class analysis (LCA) to identify and describe clinically relevant subgroups in a multinational study of patients with HR+/HER2- early breast cancer (eBC)

A. Rider, Dean Spurden, Rhys Williams, Massimo Corsaro et autres

gb, it, us (code pays fourni par la source)

82P A multinational study of real-world treatment patterns among patients with early stage HR+/HER2- breast cancer (BC)

Carmen Criscitiello, Dean Spurden, A. Rider, Rhys Williams et autres

it, gb, us (code pays fourni par la source)

PCN28 CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES

N. Harbeck, Meaghan Bartlett, Dean Spurden, Becky Hooper et autres

de, ca, gb, us (code pays fourni par la source)

PCN247 CHARACTERISTICS OF USERS AND PRESCRIBERS OF CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) AMONG MEDICARE AND NON-MEDICARE PATIENTS WITH HUMAN RECEPTOR POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC) BREAST CANCER IN THE UNITED STATES (US), 2015-2018

Allison Petrilla, Iman Mohammadi, Xuxia Shen, Dean Spurden et autres

us, gb (code pays fourni par la source)